Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications

Author:

Duenas-Gonzalez Alfonso12ORCID,Romo-Perez Adriana1ORCID,Dominguez-Gomez Guadalupe3,Chavez-Blanco Alma3,Taja-Chayeb Lucia3,Gonzalez-Fierro Aurora3,Diaz-Romero Consuelo4,Lopez-Basave Horacio Noe4

Affiliation:

1. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico

2. Instituto Nacional de Cancerología, Mexico City, Mexico

3. Division of Basic Research, Instituto Nacional de Cancerología, Mexico City, Mexico

4. Instituto Nacional de Cancerología, Mexico City, Mexico

Abstract

Background: Worldwide, gastric cancer is ranked the fifth malignancy in incidence and the third malignancy in mortality. Gastric cancer causes an altered metabolism that can be therapeutically exploited. Objective: The objective of this study is to provide an overview of the significant metabolic alterations caused by gastric cancer and propose a blockade. Methods: A comprehensive and up-to-date review of descriptive and experimental publications on the metabolic alterations caused by gastric cancer and their blockade. This is not a systematic review. Results: Gastric cancer causes high rates of glycolysis and glutaminolysis. There are increased rates of de novo fatty acid synthesis and cholesterol synthesis. Moreover, gastric cancer causes high rates of lipid turnover via fatty acid β-oxidation. Preclinical data indicate that the individual blockade of these pathways via enzyme targeting leads to antitumor effects in vitro and in vivo. Nevertheless, there is no data on the simultaneous blockade of these five pathways, which is critical as tumors show metabolic flexibility in response to the availability of nutrients. This means tumors may activate alternate routes when one or more are inhibited. We hypothesize there is a need to simultaneously block them to avoid or decrease the metabolic flexibility that may lead to treatment resistance. Conclusions: There is a need to explore the preclinical efficacy and feasibility of combined metabolic therapy targeting the pathways of glucose, glutamine, fatty acid synthesis, cholesterol synthesis, and fatty acid oxidation. This may have therapeutical implications because we have clinically available drugs that target these pathways in gastric cancer.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference112 articles.

1. Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424

2. Worthley D.L.; Phillips K.D.; Wayte N.; Schrader K.A.; Healey S.; Kaurah P.; Shulkes A.; Grimpen F.; Clouston A.; Moore D.; Cullen D.; Ormonde D.; Mounkley D.; Wen X.; Lindor N.; Carneiro F.; Huntsman D.G.; Chenevix-Trench G.; Suthers G.K.; Gastric adenocarcinoma and prox-imal polyposis of the stomach (GAPPS): A new autosomal dominant syndrome. Gut 2012,61(5),774-779

3. Carneiro F.; Wen X.; Seruca R.; Oliveira C.; Familial gastric carcinoma. Diagn Histopathol 2014,20(6),239-246

4. Oliveira C.; Pinheiro H.; Figueiredo J.; Seruca R.; Carneiro F.; Familial gastric cancer: Genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015,16(2),e60-e70

5. Sugano K.; Tack J.; Kuipers E.J.; Graham D.Y.; El-Omar E.M.; Miura S.; Haruma K.; Asaka M.; Uemura N.; Mal-fertheiner P.; Azuma T.; Bazzoli F.; Chan F.K.L.; Chen M.; Chiba N.; Chiba T.; Vas Coelho L.G.; Di Mario F.; Fock K.M.; Fukuda Y.; Genta R.M.; Goh K.L.; Katelaris P.H.; Kato M.; Kawai T.; Kushima R.; Mahachai V.; Matsuhisa T.; Miwa H.; Murakami K.; O’Morain C.A.; Rugge M.; Sato K.; Shimoyama T.; Sugiyama T.; Suzuki H.; Yagi K.; Wu M.S.; Ito M.; Kim N.; Furuta T.; Mégraud F.; Shiotani A.; Kamada T.; Kyoto global consensus report on Helicobac-ter pylori gastritis. Gut 2015,64(9),1353-1367

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3